182 related articles for article (PubMed ID: 16925156)
21. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
22. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapies in breast cancer: challenging questions from oncology nurses.
Becze E
ONS Connect; 2007; 22(8 Suppl):31-2. PubMed ID: 17824554
[No Abstract] [Full Text] [Related]
24. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer.
Kim S; Grandis JR; Rinaldo A; Takes RP; Ferlito A
Head Neck; 2008 May; 30(5):667-74. PubMed ID: 18383530
[TBL] [Abstract][Full Text] [Related]
25. Clinical research of EGFR inhibitors and related dermatologic toxicities.
Perez-Soler R; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213
[TBL] [Abstract][Full Text] [Related]
26. General management strategy for epidermal growth factor receptor inhibitor-associated papulopustular eruption.
Farahnik B; Kwong B; Murase J
J Am Acad Dermatol; 2016 Nov; 75(5):e191. PubMed ID: 27745649
[No Abstract] [Full Text] [Related]
27. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
28. Review of panitumumab: a targeted therapy.
Winkeljohn DL
Clin J Oncol Nurs; 2008 Feb; 12(1):30-2. PubMed ID: 18258571
[No Abstract] [Full Text] [Related]
29. Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
Cooper JB; Cohen EE
Head Neck; 2009 Aug; 31(8):1086-94. PubMed ID: 19378324
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
[TBL] [Abstract][Full Text] [Related]
31. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Saba NF; Khuri FR; Shin DM
Oncology (Williston Park); 2006 Feb; 20(2):153-61; discussion 162, 166, 169 passim. PubMed ID: 16562649
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor (EGFR)-inhibitors, rashes, and survival: is doxycycline the missing link?
Palma D
Oral Oncol; 2010 Apr; 46(4):e25-6. PubMed ID: 20189446
[No Abstract] [Full Text] [Related]
33. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
34. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Reimer G; Brudler O; Heinrich B; Bangerter M
MMW Fortschr Med; 2008 Dec; 150(49-50):37-8, 40. PubMed ID: 19133368
[No Abstract] [Full Text] [Related]
35. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
Dear R; Wilcken N; Shannon J
Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
[TBL] [Abstract][Full Text] [Related]
36. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
37. Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
Harari PM; Huang S
Semin Radiat Oncol; 2006 Jan; 16(1):38-44. PubMed ID: 16378905
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
39. Multidisciplinary team-working indicators of good practice in the clinical management of EGFR-inhibitor dermatologic toxicities.
Manganoni AM; Farisoglio C; Ferrari V; Zaniboni A; Beretta G; Meriggi F; Calzavara-Pinton P
Ann Surg Oncol; 2009 Jan; 16(1):224-5. PubMed ID: 18989724
[No Abstract] [Full Text] [Related]
40. Rosaceiform eruption induced by cetuximab.
Fernández-Torres R; MartÃnez Gomez W; Cuevas Santos J; Paradela S; Fonseca Capdevila E
Eur J Dermatol; 2010; 20(3):392-3. PubMed ID: 20172848
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
